While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Rybelsus (semaglutide) is a brand-name prescription medication that ... Factors such as whether a drug is a brand name or generic contribute to the tier. A drug’s tier determines a person’s copayment ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

THESE MEDICATIONS ARE MOSTLY KNOWN FOR TREATING DIABETES AND OBESITY.. BUT THE F-D-A HAS APPROVED THEM FOR PREVENTING HEART ...

Weight loss medications like Ozempic and Wegovy have become increasingly popular over the last few years. For people struggling to lose weight through diet and exercise alone, these medications ...

“So, I am pre-diabetic. And I am on semaglutide.” Semaglutide is the generic form of the drug Ozempic, according to the University of California Davis. It was approved in 2017 by the U.S. Food ...

Only 34 of 79 websites stated that compounded drugs were not FDA approved; 39 websites did not report adverse effects, warnings.

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to U.S. Food and Drug Administration approval, ...